Intravenous thrombolysis for acute ischemic stroke: a bridge between two centuries

References

• Jauch EC, Saver JL, Adams HP Jr, et al. Guidelines for the early management of patients with acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013;44(3):870–947.
   PubMed Web of Science ®Google Scholar
• Alexandrov AV. Current and future recanalization strategies for acute ischemic stroke. J Intern Med. 2010;267(2):209–219.
   PubMed Web of Science ®Google Scholar
• Meretoja A, Strbian D, Mustanoja S, et al. Reducing in-hospital delay to 20 minutes in stroke thrombolysis. Neurology. 2012;79(4):306–313.
   PubMed Web of Science ®Google Scholar
• Tsivgoulis G, Safouris A, Alexandrov AV. Safety of intravenous thrombolysis for acute ischemic stroke in specific conditions. Expert Opin Drug Saf. 2015;14(6):845–864.
   PubMed Web of Science ®Google Scholar
• Barreto AD. Intravenous thrombolytics for ischemic stroke. Neurotherapeutics. 2011;8(3):388–399.
   PubMed Web of Science ®Google Scholar
• Seners P, Turc G, Maïer B, et al. Incidence and predictors of early recanalization after intravenous thrombolysis: a systematic review and meta-analysis. Stroke. 2016;47(9):2409–2412.
   PubMed Web of Science ®Google Scholar
• Lin MP, Tsivgoulis G, Alexandrov AV, et al. Factors affecting clinical outcome in large-vessel occlusive ischemic strokes. Int J Stroke. 2015;10(4):479–484.
   PubMed Web of Science ®Google Scholar
• Riedel CH, Zimmermann P, Jensen-Kondering U, et al. The importance of size: successful recanalization by intravenous thrombolysis in acute anterior stroke depends on thrombus length. Stroke. 2011;42(6):1775–1777.
   PubMed Web of Science ®Google Scholar
• Wechsler LR. Intravenous thrombolytic therapy for acute ischemic stroke. N Engl J Med. 2011;364(22):2138–2146.
   PubMed Web of Science ®Google Scholar
• Gravanis I, Tsirka SE. Tissue-type plasminogen activator as a therapeutic target in stroke. Expert Opin Ther Targets. 2008;12(2):159–170.
   PubMed Web of Science ®Google Scholar
• Yaghi S, Eisenberger A, Willey JZ. Symptomatic intracerebral hemorrhage in acute ischemic stroke after thrombolysis with intravenous recombinant tissue plasminogen activator: a review of natural history and treatment. JAMA Neurol. 2014;71(9):1181–1185.
   PubMed Web of Science ®Google Scholar
• Lemarchand E, Maubert E, Haelewyn B, et al. Stressed neurons protect themselves by a tissue-type plasminogenactivator-mediated EGFR-dependent mechanism. Cell Death Differ. 2016;23(1):123–131.
   PubMed Web of Science ®Google Scholar
• Wu F, Wu J, Nicholson AD, et al. Tissue-type plasminogen activator regulates the neuronal uptake of glucose in the ischemic brain. J Neurosci. 2012;32(29):9848–9858.
   PubMed Web of Science ®Google Scholar
• Yip HK, Sun CK, Tsai TH, et al. Tissue plasminogen activator enhances mobilization of endothelial progenitor cells and angiogenesis in murine limb ischemia. Int J Cardiol. 2013;168(1):226–236.
   PubMed Web of Science ®Google Scholar
• Lopez-Atalaya JP, Roussel BD, Levrat D, et al. Toward safer thrombolytic agents in stroke: molecular requirements for NMDA receptor-mediated neurotoxicity. J Cereb Blood Flow Metab. 2008;28(6):1212–1221.
   PubMed Web of Science ®Google Scholar
• Copin JC, Bengualid DJ, Da Silva RF, et al. Recombinant tissue plasminogen activator induces blood-brain barrier breakdown by a matrix metalloproteinase-9-independent pathway after transient focal cerebral ischemia in mouse. Eur J Neurosci. 2011;34(7):1085–1092.
   PubMed Web of Science ®Google Scholar
• The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group. Tissue plasminogen activator for acute ischemic stroke. N Engl J Med. 1995;333(24):1581–1588.
   PubMed Web of Science ®Google Scholar
• Kwiatkowski TG, Libman RB, Frankel M, et al. Effects of tissue plasminogen activator for acute ischemic stroke at one year. National institute of neurological disorders and stroke recombinant tissue plasminogen activator stroke study group. N Engl J Med. 1999;340(23):1781–1787.
   PubMed Web of Science ®Google Scholar
• Kaste M, Thomassen L, Grond M, et al. Thrombolysis for acute ischemic stroke: a consensus statement of the 3rd karolinska stroke update, October 30-31, 2000. Stroke. 2001;32(11):2717–2718.
   PubMed Web of Science ®Google Scholar
• Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008;359(13):1317–1329.
   PubMed Web of Science ®Google Scholar
• Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The european cooperative acute stroke study (ECASS). Jama. 1995;274(13):1017–1025.
   PubMed Web of Science ®Google Scholar
• Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Second European-Australasian acute stroke study investigators. Lancet. 1998;352(9136):1245–1251.
   PubMed Web of Science ®Google Scholar
• Clark WM, Albers GW, Madden KP, et al. The rtPA (alteplase) 0– to 6–hour acute stroke trial, part A (A0276g): results of a double-blind, placebo-controlled, multicenter study. Thrombolytic therapy in acute ischemic stroke study investigators. Stroke. 2000;31(4):811–816.
   PubMed Web of Science ®Google Scholar
• Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (Alteplase) for ischemic stroke 3 to 5 hours after symptom onset. The ATLANTIS study: a randomized controlled trial. alteplase thrombolysis for acute noninterventional therapy in ischemic stroke. Jama. 1999;282(21):2019–2026.
   PubMed Web of Science ®Google Scholar
• Davis SM, Donnan G, Parsons MW. Effects of alteplase beyond 3 h after stroke in the echoplanar imaging thrombolytic evaluation trial (EPITHET): a placebo-controlled randomised trial. Lancet Neurol. 2008;7(4):299–309.
   PubMed Web of Science ®Google Scholar
• Sandercock P, Wardlaw JM, Lindley RI, et al. The benefits and harms of intravenous thrombolysis with recombinant tissue plasminogen activator within 6 h of acute ischaemic stroke (the third international stroketrial [IST-3]): a randomised controlled trial. Lancet. 2012;379(9834):2352–2363.
   PubMed Web of Science ®Google Scholar
• Emberson J, Lees KR, Lyden P, et al. Stroke Thrombolysis Trialists’ Collaborative Group. Effect of treatment delay, age, and stroke severity on the effects of intravenous thrombolysis with alteplase for acute ischaemic stroke: a meta-analysis of individual patient data from randomised trials. Lancet. 2014;384(9958):1929–1935.
   PubMed Web of Science ®Google Scholar
• Fagan SC, Morgenstern LB, Petitta A, et al. Cost-effectiveness of tissue plasminogen activator for acute ischemic stroke. NINDS rt-PA Stroke Study Group. Neurology. 1998;50(4):883–890.
   PubMed Web of Science ®Google Scholar
• Whiteley WN, Emberson J, Lees KR, et al. Risk of intracerebral haemorrhage with alteplase after acute ischaemic stroke: a secondary analysis of an individual patient data meta-analysis. Lancet Neurol. 2016;15(9):925–933.
   PubMed Web of Science ®Google Scholar
• Saqqur M, Tsivgoulis G, Molina CA, et al. Symptomatic intracerebral hemorrhage and recanalization after IV rt-PA: a multicenter study. Neurology. 2008;71(17):1304–1312.
   PubMed Web of Science ®Google Scholar
• Strbian D, Michel P, Seiffge DJ, et al. Symptomatic intracranial hemorrhage after stroke thrombolysis: comparison of prediction scores. Stroke. 2014;45(3):752–758.
   PubMed Web of Science ®Google Scholar
• Strbian D, Engelter S, Michel P, et al. Symptomatic intracranial hemorrhage after stroke thrombolysis: the SEDAN score. Ann Neurol. 2012;71(5):634–641.
   PubMed Web of Science ®Google Scholar
• Barber PA, Demchuk AM, Zhang J, et al. Validity and reliability of a quantitative computed tomography score in predicting outcome of hyperacute stroke before thrombolytic therapy. ASPECTS Study Group. alberta stroke programme early ct score. Lancet. 2000;355(9216):1670–1674.
   PubMed Web of Science ®Google Scholar
• Wasser K, Papanagiotou P, Brunner F, et al. Impact of ASPECTS on computed tomography angiography source images on outcome after thrombolysis or endovascular therapy in large vessel occlusions. Eur J Neurol. 2016;23(11):1599–1605.
   PubMed Web of Science ®Google Scholar
• Tsivgoulis G, Kotsis V, Giannopoulos S. Intravenous thrombolysis for acute ischaemic stroke: effective blood pressure control matters. Int J Stroke. 2011;6(2):125–127.
   PubMed Web of Science ®Google Scholar
• Ahmed N, Wahlgren N, Brainin M, et al.; SITS Investigators. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis: retrospective analysis from safe implementation of thrombolysis in stroke-international stroke thrombolysis register (SITS-ISTR). Stroke. 2009;40(7):2442–2449.
   PubMed Web of Science ®Google Scholar
• Tsivgoulis G, Frey JL, Flaster M, et al. Pre-tissue plasminogen activator blood pressure levels and risk of symptomatic intracerebral hemorrhage. Stroke. 2009;40(11):3631–3634.
   PubMed Web of Science ®Google Scholar
• O’Carroll CB, Aguilar MI. Management of postthrombolysis hemorrhagic and orolingual angioedema complications. Neurohospitalist. 2015;5(3):133–141.
   PubMedGoogle Scholar
• Myslimi F, Caparros F, Dequatre-Ponchelle N, et al. Orolingual angioedema during or after thrombolysis fo.r cerebral ischemia. Stroke. 2016;47(7):1825–1830.
   PubMed Web of Science ®Google Scholar
• Haršány M, Tsivgoulis G, Alexandrov AV. Intravenous thrombolysis in acute ischemic stroke: standard and potential future applications. Expert Rev Neurother. 2014;14(8):879–892.
   PubMed Web of Science ®Google Scholar
• Van Schaik SM, Scott S, De Lau LM, et al. Short door-to-needle times in acute ischemic stroke and prospective identification of its delaying factors. Cerebrovasc Dis Extra. 2015;5(2):75–83.
   PubMedGoogle Scholar
• Zaidi SF, Shawver J, Espinosa Morales A, et al. Stroke care: initial data from a county-based bypass protocol for patients with acute stroke. J Neurointerv Surg. 2016;pii:neurintsurg-2016-012476.
   Google Scholar
• Benavente L, Villanueva MJ, Vega P, et al. Code stroke in asturias. Neurologia. 2016;31(3):143–148.
   PubMed Web of Science ®Google Scholar
• Zinkstok SM, Beenen LF, Luitse JS, et al. Thrombolysis in stroke within 30 minutes: results of the acutebrain care intervention study. PLoS One. 2016;11(11):e0166668.
   PubMed Web of Science ®Google Scholar
• Kepplinger J, Barlinn K, Deckert S, et al. Safety and efficacy of thrombolysis in telestroke: A systematic review and meta-analysis. Neurology. 2016;87(13):1344–1351.
   PubMed Web of Science ®Google Scholar
• Anderson CS, Robinson T, Lindley RI, et al. Low-dose versus standard-dose intravenous alteplase in acute ischemic stroke. N Engl J Med. 2016;374(24):2313–2323.
   PubMed Web of Science ®Google Scholar
• Yamaguchi T, Mori E, Minematsu K, et al.; Japan Alteplase Clinical Trial (J-ACT) Group. Alteplase at 0.6 mg/kg for acute ischemic stroke within 3 hours of onset: Japan alteplase clinical trial (J-ACT). Stroke. 2006;37(7):1810–1815.
   PubMed Web of Science ®Google Scholar
• Toyoda K, Koga M, Naganuma M, et al. Routine use of intravenous low-dose recombinant tissue plasminogen activator in Japanese patients: general outcomes and prognostic factors from the SAMURAI register. Stroke. 2009;40(11):3591–3595.
   PubMed Web of Science ®Google Scholar
• Sila C. Finding the Right t-PA Dose for Asians with Acute Ischemic Stroke. N Engl J Med. 2016;374(24):2389–23890.
   PubMed Web of Science ®Google Scholar
• Acheampong P, May MT, Ford GA, et al. Bolus-infusion delays of alteplase during thrombolysis in acute ischaemic stroke and functional outcome at 3 months. Stroke Res Treat.  2014;2014:358640.
   PubMedGoogle Scholar
• Brodoehl S, Günther A, Witte OW, et al. How to manage thrombolysis interruptions in acute stroke? Clin Neuropharmacol. 2015;38(3):85–88.
   PubMed Web of Science ®Google Scholar
• Walter S, Kostopoulos P, Haass A, et al. Diagnosis and treatment of patients with stroke in a mobile stroke unit versus in hospital: a randomised controlled trial. Lancet Neurol. 2012;11(5):397–404.
   PubMed Web of Science ®Google Scholar
• Ebinger M, Winter B, Wendt M, et al. Effect of the use of ambulance-based thrombolysis on time to thrombolysis in acute ischemic stroke: a randomized clinical trial. Jama. 2014;311(16):1622–1631.
   PubMed Web of Science ®Google Scholar
• Parker SA, Bowry R, Wu TC, et al. Establishing the first mobile stroke unit in the United States. Stroke. 2015;46(5):1384–1391.
   PubMed Web of Science ®Google Scholar
• Itrat A, Taqui A, Cerejo R, et al. Telemedicine in prehospital stroke evaluation and thrombolysis: taking stroke treatment to the doorstep. JAMA Neurol. 2016;73(2):162–168.
   PubMed Web of Science ®Google Scholar
• Tsivgoulis G, Katsanos AH, Kadlecová P, et al. Intravenous thrombolysis for ischemic stroke in the golden hour: propensity-matched analysis from the SITS-EAST registry. J Neurol. 2017;264:912–920. DOI:10.1007/s00415-017-8461-8
   PubMed Web of Science ®Google Scholar
• Nasr DM, Brinjikji W, Cloft HJ, et al. Utilization of intravenous thrombolysis is increasing in the United States. Int J Stroke. 2013;8(8):681–688.
   PubMed Web of Science ®Google Scholar
• Demaerschalk BM. Alteplase treatment in acute stroke: incorporating food and drug administration prescribing information into existing acute stroke management guide. Curr Atheroscler Rep. 2016;18(8):53.
   PubMed Web of Science ®Google Scholar
• Demaerschalk BM, Kleindorfer DO, Adeoye OM, et al. American Heart Association stroke council and council on epidemiology and prevention. scientific rationale for the inclusion and exclusion criteria for intravenous alteplase in acute ischemic stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2016;47(2):581–641.
   PubMed Web of Science ®Google Scholar
• Label for ACTIVASE [Supplement 5203, Action Date 02/13/2015]. http://www.accessdata.fda.gov/drugsatfda_docs/label/2015/103172s5203lbl.pdf
   Google Scholar
• Actilyse [Last Updated on eMC 08-May-2017]. https://www.medicines.org.uk/emc/medicine/308
   Google Scholar
• Karolinska stroke update 2008, final draft per 20081118 ESO GC Statement on revised guidelines for intravenous thrombolysis. http://www.strokeupdate.org/Cons_thrombolysis_2008.aspx
   Google Scholar
• George BP, Asemota AO, Dorsey ER, et al. United States trends in thrombolysis for older adults with acute ischemic stroke. Clin Neurol Neurosurg. 2015;139:16–23.
   PubMed Web of Science ®Google Scholar
• Arora R, Salamon E, Katz JM, et al. Use and outcomes of intravenous thrombolysis for acute ischemic stroke in patients ≥90 years of age. Stroke. 2016;47(9):2347–2354.
   PubMed Web of Science ®Google Scholar
• Paciaroni M, Balucani C, Agnelli G, et al. Systemic thrombolysis in patients with acute ischemic stroke and internal carotid artery occlusion: the ICARO study. Stroke. 2012;43(1):125–130.
   PubMed Web of Science ®Google Scholar
• Paciaroni M, Inzitari D, Agnelli G, et al. Intravenous thrombolysis or endovascular therapy for acute ischemic stroke associated with cervical internal carotid artery occlusion: the ICARO-3 study. J Neurol. 2015;262(2):459–468.
   PubMed Web of Science ®Google Scholar
• Paciaroni M, Agnelli G, Caso V, et al. Intravenous thrombolysis for acute ischemic stroke associated to extracranial internal carotid artery occlusion: the ICARO-2 study. Cerebrovasc Dis. 2012;34(5–6):430–445.
   PubMed Web of Science ®Google Scholar
• Zinkstok SM, Vergouwen MD, Engelter ST, et al. Safety and functional outcome of thrombolysis in dissection-related ischemic stroke: a meta-analysis of individual patient data. Stroke. 2011;42(9):2515–2520.
   PubMed Web of Science ®Google Scholar
• Tsivgoulis G, Zand R, Katsanos AH, et al. Safety and outcomes of intravenous thrombolysis in dissection-related ischemic stroke: an international multicenter study and comprehensive meta-analysis of reported case series. J Neurol. 2015;262(9):2135–2143.
   PubMed Web of Science ®Google Scholar
• Lin J, Sun Y, Zhao S, et al. Safety and efficacy of thrombolysis in cervical artery dissection-related ischemic stroke: a meta-analysis of observational studies. Cerebrovasc Dis. 2016;42(3–4):272–279.
   PubMed Web of Science ®Google Scholar
• Kwon JY, Kim NY, Suh DC, et al. Intracranial and extracranial arterial dissection presenting with ischemic stroke: lesion location and stroke mechanism. J Neurol Sci. 2015;358(1–2):371–376.
   PubMed Web of Science ®Google Scholar
• Patel MR, Meine TJ, Lindblad L. Cardiac tamponade in the fibrinolytic era: analysis of >100,000 patients with ST-segment elevation myocardial infarction. Am Heart J. 2006;151(2):316–322.
   PubMed Web of Science ®Google Scholar
• Kasner SE, Villar-Cordova CE, Tong D, et al. Hemopericardium and cardiac tamponade after thrombolysis for acute ischemic stroke. Neurology. 1998;50(6):1857–1859.
   PubMed Web of Science ®Google Scholar
• Kremen SA, Wu MN, Ovbiagele B. Hemopericardium following intravenous thrombolysis for acute ischemic stroke. Cerebrovasc Dis. 2005;20(6):478–479.
   PubMed Web of Science ®Google Scholar
• Witt BJ, Brown RD Jr, Jacobsen SJ, et al. A community-based study of stroke incidence after myocardial infarction. Ann Intern Med. 2005;143(11):785–792.
   PubMed Web of Science ®Google Scholar
• Becker RC, Hochman JS, Cannon CP, et al. Fatal cardiac rupture among patients treated with thrombolytic agents and adjunctive thrombin antagonists: observations from the thrombolysis and thrombin inhibition in myocardial infarction 9 study. J Am Coll Cardiol. 1999;33(2):479–487.
   PubMed Web of Science ®Google Scholar
• De Silva DA, Manzano JJ, Chang HM, et al. Reconsidering recent myocardial infarction as a contraindication for IV stroke thrombolysis. Neurology. 2011;76(21):1838–1840.
   PubMed Web of Science ®Google Scholar
• Maciel R, Palma R, Sousa P, et al. Acute stroke with concomitant acute myocardial infarction: will you thrombolyse? J Stroke. 2015;17(1):84–86.
   PubMed Web of Science ®Google Scholar
• Khatri P, Kasner SE. Ischemic strokes after cardiac catheterization: opportune thrombolysis candidates? Arch Neurol. 2006;63(6):817–821.
   PubMedGoogle Scholar
• Khatri P, Taylor RA, Palumbo V, et al.; Treatment of Acute Stroke after Cardiac Catheterization (TASCC) Study Group. The safety and efficacy of thrombolysis for strokes after cardiac catheterization. J Am Coll Cardiol. 2008;51(9):906–911.
   PubMed Web of Science ®Google Scholar
• Barber PA, Zhang J, Demchuk AM, et al. Why are stroke patients excluded from TPA therapy? An analysis of patient eligibility. Neurology. 2001;56(8):1015–1020.
   PubMed Web of Science ®Google Scholar
• Ali SF, Siddiqui K, Ay H, et al. Baseline predictors of poor outcome in patients too good to treat with intravenous thrombolysis. Stroke. 2016;47(12):2986–2992.
   PubMed Web of Science ®Google Scholar
• Romano JG, Smith EE, Liang L, et al. Outcomes in mild acute ischemic stroke treated with intravenous thrombolysis: a retrospective analysis of the get with the guidelines-stroke registry. JAMA Neurol. 2015;72(4):423–431.
   PubMed Web of Science ®Google Scholar
• Mackey J, Kleindorfer D, Sucharew H, et al. Population-based study of wake-up strokes. Neurology. 2011;76(19):1662–1667.
   PubMed Web of Science ®Google Scholar
• Costa R, Pinho J, Alves JN, et al. Wake-up stroke and stroke within the therapeutic window for thrombolysis have similar clinical severity, imaging characteristics, and outcome. J Stroke Cerebrovasc Dis. 2016;25(3):511–514.
   PubMed Web of Science ®Google Scholar
• Rimmele DL, Thomalla G. Wake-up stroke: clinical characteristics, imaging findings, and treatment option - an update. Front Neurol. 2014;26(5):35.
   Google Scholar
• Elliott WJ. Circadian variation in the timing of stroke onset: a meta-analysis. Stroke. 1998;29(5):992–996.
   PubMed Web of Science ®Google Scholar
• Silva GS, Lima FO, Camargo EC, et al. Wake-up stroke: clinical and neuroimaging characteristics. Cerebrovasc Dis. 2010;29(4):336–342.
   PubMed Web of Science ®Google Scholar
• Thomalla G, Fiebach JB, Østergaard L, et al. A multicenter, randomized, double-blind, placebo-controlled trial to test efficacy and safety of magnetic resonance imaging-based thrombolysis in wake-up stroke (WAKE-UP). Int J Stroke. 2014;9(6):829–836.
   PubMed Web of Science ®Google Scholar
• Koga M, Toyoda K, Kimura K, et al. Thrombolysis for acute wake-up and unclear-onset strokes with alteplase at 0·6 mg/kg (THAWS) trial. Int J Stroke. 2014;9(8):1117–1124.
   PubMed Web of Science ®Google Scholar
• A Study of Intravenous Thrombolysis With Alteplase in MRI-Selected Patients (MR WITNESS). https://clinicaltrials.gov/ct2/show/NCT01282242
   Google Scholar
• Thomalla G, Boutitie F, Fiebach JB, et al. Stroke with unknown time of symptom onset: baseline clinical and magnetic resonance imaging data of the first thousand patients in WAKE-UP. Stroke. 2017;48(3):770–773.
   PubMed Web of Science ®Google Scholar
• Petkova M, Rodrigo S, Lamy C, et al. MR imaging helps predict time from symptom onset in patients with acute stroke: implications for patients with unknown onset time. Radiology. 2010;257(3):782–792.
   PubMed Web of Science ®Google Scholar
• Cho AH, Sohn SI, Han MK, et al. Safety and efficacy of MRI-based thrombolysis in unclear-onset stroke. A preliminary report. Cerebrovasc Dis. 2008;25(6):572–579.
   PubMed Web of Science ®Google Scholar
• Schwamm LH. IV alteplase in mr-selected patients with stroke of unknown onset is safe and feasible: results of the multicenter MR WITNESS trial. Stroke. 2016;47:LB23.
   Google Scholar
• Barreto AD, Fanale CV, Alexandrov AV, et al. Prospective, open-label safety study of intravenous recombinanttissue plasminogen activator in wake-up stroke. Ann Neurol. 2016;80(2):211–218.
   PubMed Web of Science ®Google Scholar
• Barreto AD, Martin-Schild S, Hallevi H, et al. Thrombolytic therapy for patients who wake-up with stroke. Stroke. 2009;40(3):827–832.
   PubMed Web of Science ®Google Scholar
• Bai Q, Zhao Z, Fu P, et al. Clinical outcomes of fast MRI-based thrombolysis in wake-up strokes compared to superacute ischemic strokes within 12 hours. Neurol Res. 2013;35(5):492–497.
   PubMed Web of Science ®Google Scholar
• Aoki J, Kimura K, Iguchi Y, et al. Intravenous thrombolysis based on diffusion-weighted imaging and fluid-attenuated inversion recovery mismatch in acute stroke patients with unknown onset time. Cerebrovasc Dis. 2011;31(5):435–441.
   PubMed Web of Science ®Google Scholar
• Stryker Announces an Early Stop to Enrollment in the DAWN™ Trial Due to the High Probability of Trial Success. http://www.prweb.com/releases/2017/03/prweb14129893.htm
   Google Scholar
• Linn J. Imaging of cerebral microbleeds. Clin Neuroradiol. 2015;25(Suppl 2):167–175.
   PubMed Web of Science ®Google Scholar
• Fiehler J, Albers GW, Boulanger JM, et al. Bleeding risk analysis in stroke imaging before thromboLysis (BRASIL): pooled analysis of T2*-weighted magnetic resonance imaging data from 570 patients. Stroke. 2007;38(10):2738–2744.
   PubMed Web of Science ®Google Scholar
• Charidimou A, Kakar P, Fox Z, et al. Cerebral microbleeds and the risk of intracerebral haemorrhage after thrombolysis for acute ischaemic stroke: systematic review and meta-analysis. J Neurol Neurosurg Psychiatry. 2013;84(3):277–280.
   PubMed Web of Science ®Google Scholar
• Shoamanesh A, Kwok CS, Lim PA, et al. Postthrombolysis intracranial hemorrhage risk of cerebral microbleeds in acute stroke patients: a systematic review and meta-analysis. Int J Stroke. 2013;8(5):348–356.
   PubMed Web of Science ®Google Scholar
• Zand R, Tsivgoulis G, Singh M, et al. Cerebral microbleeds and risk of intracerebral hemorrhage post intravenous thrombolysis. J Stroke Cerebrovasc Dis. 2017;26(3):538–544.
   PubMed Web of Science ®Google Scholar
• Tsivgoulis G, Zand R, Katsanos AH, et al. Risk of symptomatic intracerebral hemorrhage after intravenous thrombolysis in patients with acute ischemic stroke and high cerebral microbleed burden: a meta-analysis. JAMA Neurol. 2016;73(6):675–683.
   PubMed Web of Science ®Google Scholar
• Charidimou A, Pasi M, Fiorelli M, et al. Leukoaraiosis, cerebral hemorrhage, and outcome after intravenous thrombolysis for acute ischemic stroke: a meta-analysis (v1). Stroke. 2016;47(9):2364–2372.
   PubMed Web of Science ®Google Scholar
• Lin Q, Li Z, Wei R, et al. Increased risk of post-thrombolysis intracranial hemorrhage in acute ischemic stroke patients with leukoaraiosis: a meta-analysis. PLoS One. 2016;11(4):e0153486.
   PubMed Web of Science ®Google Scholar
• Kongbunkiat K, Wilson D, Kasemsap N, et al. Leukoaraiosis, intracerebral hemorrhage, and functional outcome after acute stroke thrombolysis. Neurology. 2017;88(7):638–645.
   PubMed Web of Science ®Google Scholar
• Vlak MH, Algra A, Brandenburg R, et al. Prevalence of unruptured intracranial aneurysms, with emphasis on sex, age, comorbidity, country, and time period: a systematic review and meta-analysis. Lancet Neurol. 2011;10(7):626–636.
   PubMed Web of Science ®Google Scholar
• Edwards NJ, Kamel H, Josephson SA. The safety of intravenous thrombolysis for ischemic stroke in patients with pre-existing cerebral aneurysms: a case series and review of the literature. Stroke. 2012;43(2):412–416.
   PubMed Web of Science ®Google Scholar
• Sheth KN, Shah N, Morovati T, et al. Intravenous rt-PA is not associated with increased risk of hemorrhage in patients with intracranial aneurysms. Neurocrit Care. 2012;17(2):199–203.
   PubMed Web of Science ®Google Scholar
• Mittal MK, Seet RC, Zhang Y, et al. Safety of intravenous thrombolysis in acute ischemic stroke patients with saccular intracranial aneurysms. J Stroke Cerebrovasc Dis. 2013;22(5):639–643.
   PubMed Web of Science ®Google Scholar
• Mowla A, Singh K, Mehla S, et al. Is acute reperfusion therapy safe in acute ischemic stroke patients who harbor unruptured intracranial aneurysm? Int J Stroke. 2015;10(Suppl A100):113–118.
   PubMed Web of Science ®Google Scholar
• Goyal N, Tsivgoulis G, Zand R, et al. Systemic thrombolysis in acute ischemic stroke patients with unruptured intracranial aneurysms. Neurology. 2015;85(17):1452–1458.
   PubMed Web of Science ®Google Scholar
• Etgen T, Steinich I, Gsottschneider L. Thrombolysis for ischemic stroke in patients with brain tumors. J Stroke Cerebrovasc Dis. 2014;23(2):361–366.
   PubMed Web of Science ®Google Scholar
• Singh K, Mowla A, Mehla S, et al. Safety of intravenous thrombolysis for acute ischemic stroke in patients with preexisting intracranial neoplasms: a case series. Int J Stroke. 2015;10(3):E29–E30.
   PubMed Web of Science ®Google Scholar
• Murthy SB, Moradiya Y, Shah S, et al. In-hospital outcomes of thrombolysis for acute ischemic stroke in patients with primary brain tumors. J Clin Neurosci. 2015;22(3):474–478.
   PubMed Web of Science ®Google Scholar
• Morgenstern LB, Frankowski RF. Brain tumor masquerading as stroke. J Neurooncol. 1999;44(1):47–52.
   PubMed Web of Science ®Google Scholar
• Diedler J, Ahmed N, Sykora M, et al. Safety of intravenous thrombolysis for acute ischemic stroke in patients receiving antiplatelet therapy at stroke onset. Stroke. 2010;41(2):288–294.
   PubMed Web of Science ®Google Scholar
• Pan X, Zhu Y, Zheng D, et al. Prior antiplatelet agent use and outcomes after intravenous thrombolysis with recombinant tissue plasminogen activator in acute ischemic stroke: a meta-analysis of cohort studies and randomized controlled trials. Int J Stroke. 2015;10(3):317–323.
   PubMed Web of Science ®Google Scholar
• Shahjouei S, Tsivgoulis G, Bavarsad Shahripour R, et al. Safety of intravenous thrombolysis among stroke patients taking new oral anticoagulants–case series and systematic review of reported cases. J Stroke Cerebrovasc Dis. 2015;24(12):2685–2693.
   PubMed Web of Science ®Google Scholar
• Seiffge DJ, Hooff RJ, Nolte CH, et al. Recanalization therapies in acute ischemic stroke patients: impact of prior treatment with novel oral anticoagulants on bleeding complications and outcome. Circulation. 2015;132(13):1261–1269.
   PubMed Web of Science ®Google Scholar
• Xian Y, Federspiel JJ, Hernandez AF, et al. Use of intravenous recombinant tissue plasminogen activator in acute ischemic stroke patients taking non-vitamin K antagonist oral anticoagulants (NOACs) before stroke. Circulation. 2017;135(11):1024–1035.
   PubMed Web of Science ®Google Scholar
• Berrouschot J, Stoll A, Hogh T, et al. Intravenous thrombolysis with recombinant tissue-type plasminogen activator in a stroke patient receiving dabigatran anticoagulant after antagonization with idarucizumab. Stroke. 2016;47(7):1936–1938.
   PubMed Web of Science ®Google Scholar
• Diener HC, Bernstein R, Butcher K, et al. Thrombolysis and thrombectomy in patients treated with dabigatran with acute ischemic stroke: expertopinion. Int J Stroke. 2017;12(1):9–12.
   PubMed Web of Science ®Google Scholar
• Tütüncü S, Ziegler AM, Scheitz JF, et al. Severe renal impairment is associated with symptomatic intracerebral hemorrhage after thrombolysis for ischemic stroke. Stroke. 2013;44(11):3217–3219.
   PubMed Web of Science ®Google Scholar
• Hao Z, Yang C, Liu M, et al. Renal dysfunction and thrombolytic therapy in patients with acute ischemic stroke: a systematic review and meta-analysis. Medicine (Baltimore). 2014;93(28):e286.
   PubMed Web of Science ®Google Scholar
• Jung JM, Kim HJ, Ahn H, et al. Chronic kidney disease and intravenous thrombolysis in acute stroke: A systematic review and meta-analysis. J Neurol Sci. 2015;358(1–2):345–350.
   PubMed Web of Science ®Google Scholar
• Mazya M, Egido JA, Ford GA, et al. Predicting the risk of symptomatic intracerebral hemorrhage in ischemic stroke treated with intravenous alteplase: safe Implementation of Treatments in Stroke (SITS) symptomatic intracerebral hemorrhage risk score. Stroke. 2012;43(6):1524–1531.
   PubMed Web of Science ®Google Scholar
• Lyerly MJ, Houston JT, Boehme AK, et al. Safety of intravenous tissue plasminogen activator administration with computed tomography evidence of prior infarction. J Stroke Cerebrovasc Dis. 2014;23(6):1657–1661.
   PubMed Web of Science ®Google Scholar
• Kahles T, Mono ML, Heldner MR, et al. Repeated intravenous thrombolysis for early recurrent stroke: challenging the exclusion criterion. Stroke. 2016;47(8):2133–2135.
   PubMed Web of Science ®Google Scholar
• Lindley RI, Wardlaw JM, Whiteley WN, et al. Alteplase for acute ischemic stroke: outcomes by clinically important subgroups in the third international stroke trial. Stroke. 2015;46(3):746–756.
   PubMed Web of Science ®Google Scholar
• Murthy SB, Karanth S, Shah S, et al. Thrombolysis for acute ischemic stroke in patients with cancer: a population study. Stroke. 2013;44(12):3573–3576.
   PubMed Web of Science ®Google Scholar
• Cutting S, Wettengel M, Conners JJ, et al. Three-month outcomes are poor in stroke patients with cancer despite acute stroke treatment. J Stroke Cerebrovasc Dis. 2017;26(4):809–815.
   PubMed Web of Science ®Google Scholar
• Merino JG, Luby M, Benson RT, et al. Predictors of acute stroke mimics in 8187 patients referred to a stroke service. J Stroke Cerebrovasc Dis. 2013;22(8):e397–e403.
   PubMed Web of Science ®Google Scholar
• Liberman AL, Prabhakaran S. Stroke chameleons and stroke mimics in the emergency department. Curr Neurol Neurosci Rep. 2017;17(2):15.
   PubMed Web of Science ®Google Scholar
• Brown DL, Barsan WG, Lisabeth LD, et al. Survey of emergency physicians about recombinant tissue plasminogen activator for acute ischemic stroke. Ann Emerg Med. 2005;46(1):56–60.
   PubMed Web of Science ®Google Scholar
• Tsivgoulis G, Zand R, Katsanos AH, et al. Safety of intravenous thrombolysis in stroke mimics: prospective 5-year study and comprehensive meta-analysis. Stroke. 2015;46(5):1281–1287.
   PubMed Web of Science ®Google Scholar
• Goyal N, Tsivgoulis G, Male S, et al. FABS: an intuitive tool for screening of stroke mimics in the emergency department. Stroke. 2016;47(9):2216–2220.
   PubMed Web of Science ®Google Scholar
• Gartman EJ. The use of thrombolytic therapy in pregnancy. Obstet Med. 2013;6(3):105–111.
   PubMedGoogle Scholar
• Murugappan A, Coplin WM, Al-Sadat AN, et al. Thrombolytic therapy of acute ischemic stroke during pregnancy. Neurology. 2006;66(5):768–770.
   PubMed Web of Science ®Google Scholar
• Reining-Festa A, Földy D, Coulibaly-Wimmer M, et al. Intravenous thrombolysis of stroke in early pregnancy: a case report and review of the literature. J Neurol. 2017;264(2):397–400.
   PubMed Web of Science ®Google Scholar
• Gandhi SK, McKinney JS, Sedjro JE, et al. Temporal trends in incidence and long-term case fatality of stroke among children from 1994 to 2007. Neurology. 2012;78(24):1923–1929.
   PubMed Web of Science ®Google Scholar
• Nasr DM, Biller J, Rabinstein AA. Use and in-hospital outcomes of recombinant tissue plasminogen activator in pediatric arterial ischemic stroke patients. Pediatr Neurol. 2014;51(5):624–631.
   PubMed Web of Science ®Google Scholar
• Rivkin MJ, deVeber G, Ichord RN, et al. Thrombolysis in pediatric stroke study. Stroke. 2015;46(3):880–885.
   PubMed Web of Science ®Google Scholar
• Steinlin M, Mackay MT. Emergency management of ischemic stroke in children. Curr Treat Options Neurol. 2015;17(5):349.
   PubMed Web of Science ®Google Scholar
• Campbell BC, Donnan GA, Lees KR, et al. Endovascular stent thrombectomy: the new standard of care for large vessel ischaemic stroke. Lancet Neurol. 2015;14(8):846–854.
   PubMed Web of Science ®Google Scholar
• Powers WJ, Derdeyn CP, Biller J, et al. 2015 American Heart Association/American Stroke Association focused update of the 2013 guidelines for the early management of patients with acute ischemic stroke regarding endovascular treatment: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2015;46(10):3020–3035.
   PubMed Web of Science ®Google Scholar
• Goyal M, Menon BK, van Zwam WH, et al. Endovascular thrombectomy after large-vessel ischaemic stroke: a meta-analysis of individual patient data from five randomised trials. Lancet. 2016;387(10029):1723–1731.
   PubMed Web of Science ®Google Scholar
• Fiehler J, Cognard C, Gallitelli M, et al. European recommendations on organisation of interventional care in acute stroke (EROICAS). Int J Stroke. 2016;11(6):701–716.
   PubMed Web of Science ®Google Scholar
• Tsivgoulis G, Katsanos AH, Mavridis D, et al. Mechanical thrombectomy improves functional outcomes independent of pretreatment with intravenous thrombolysis. Stroke. 2016;47(6):1661–1664.
   PubMed Web of Science ®Google Scholar
• Broeg-Morvay A, Mordasini P, Bernasconi C, et al. Direct mechanical intervention versus combined intravenous and mechanical intervention in large artery anterior circulation stroke: a matched-pairs analysis. Stroke. 2016;47(4):1037–1044.
   PubMed Web of Science ®Google Scholar
• Weber R, Nordmeyer H, Hadisurya J, et al. Comparison of outcome and interventional complication rate in patients with acute stroke treated with mechanical thrombectomy with and without bridging thrombolysis. J Neurointerv Surg. 2017;9(3):229–233.
   PubMed Web of Science ®Google Scholar
• Grotta JC, Hacke W. Stroke neurologist’s perspective on the new endovascular trials. Stroke. 2015;46(6):1447–1452.
   PubMed Web of Science ®Google Scholar
• Tsivgoulis G, Safouris A, Krogias C, et al. Endovascular reperfusion therapies for acute ischemic stroke: dissecting the evidence. Expert Rev Neurother. 2016;16(5):527–534.
   PubMed Web of Science ®Google Scholar
• Ganesh A, Al-Ajlan FS, Sabiq F, et al.; ESCAPE Trial Investigators. Infarct in a new territory after treatment administration in the ESCAPE randomized controlled trial (endovascular treatment for small core and anterior circulation proximal occlusion with emphasis on minimizing CT to recanalization times). Stroke. 2016;47(12):2993–2998.
   PubMed Web of Science ®Google Scholar
• Southerland AM, Johnston KC, Molina CA, et al. Suspected large vessel occlusion: should emergency medical services transport to the nearest primary stroke center or bypass to a comprehensive stroke center with endovascular capabilities? Stroke. 2016;47(7):1965–1967.
   PubMed Web of Science ®Google Scholar
• Tsivgoulis G, Katsanos AH, Mavridis D, et al. Endovascular thrombectomy with or without systemic thrombolysis? Ther Adv Neurol Disord. 2017;10(3):151–160.
   PubMed Web of Science ®Google Scholar
• Milne MS, Holodinsky JK, Hill MD, et al. Drip ‘n ship versus mothership for endovascular treatment: modeling the best transportation options for optimal outcomes. Stroke. 2017;48(3):791–794.
   PubMed Web of Science ®Google Scholar
• Turc G, Maïer B, Naggara O, et al. Clinical scales do not reliably identify acute ischemic stroke patients with large-artery occlusion. Stroke. 2016;47(6):1466–1472.
   PubMed Web of Science ®Google Scholar
• Perez de la Ossa N, Carrera D, Gorchs M, et al. Design and validation of a prehospital stroke scale to predict large arterial occlusion: the rapid arterial occlusion evaluation scale. Stroke. 2014;45(1):87–91.
   PubMed Web of Science ®Google Scholar
• Kothari RU, Pancioli A, Liu T, et al. Cincinnati. Prehospital stroke scale: reproducibility and validity. Ann Emerg Med. 1999;33(4):373–378.
   PubMed Web of Science ®Google Scholar
• Hastrup S, Damgaard D, Johnsen SP, et al. Prehospital acute stroke severity scale to predict large artery occlusion: design and comparison with other scales. Stroke. 2016;47(7):1772–1776.
   PubMed Web of Science ®Google Scholar
• Hacke W, Albers G, Al-Rawi Y, et al. The desmoteplase in acute ischemic stroke trial (DIAS): a phase II MRI-based 9-hour window acute stroke thrombolysis trial with intravenous desmoteplase. Stroke. 2005;36(1):66–73.
   PubMed Web of Science ®Google Scholar
• Furlan AJ, Eyding D, Albers GW, et al. Dose escalation of desmoteplase for acute ischemic stroke (DEDAS): evidence of safety and efficacy 3 to 9 hours after stroke onset. Stroke. 2006;37(5):1227–1231.
   PubMed Web of Science ®Google Scholar
• Hacke W, Furlan AJ, Al-Rawi Y, et al. Intravenous desmoteplase in patients with acute ischaemic stroke selected by MRI perfusion-diffusion weighted imaging or perfusion CT (DIAS-2): a prospective, randomised, double-blind, placebo-controlled study. Lancet Neurol. 2009;8(2):141–150.
   PubMed Web of Science ®Google Scholar
• Albers GW, von Kummer R, Truelsen T, et al. Safety and efficacy of desmoteplase given 3-9 h after ischaemic stroke in patients with occlusion or high-grade stenosis in major cerebral arteries (DIAS-3): a double-blind, randomised, placebo-controlled phase 3 trial. Lancet Neurol. 2015;14(6):575–584.
   PubMed Web of Science ®Google Scholar
• von Kummer R, Mori E, Truelsen T, et al. Desmoteplase 3 to 9 hours after major artery occlusion stroke: the DIAS-4 trial (efficacy and safety study of desmoteplase to treat acute ischemic stroke). Stroke. 2016;47(12):2880–2887.
   PubMed Web of Science ®Google Scholar
• Tanswell P, Modi N, Combs D, et al. Pharmacokinetics and pharmacodynamics of tenecteplase in fibrinolytic therapy of acute myocardial infarction. Clin Pharmacokinet. 2002;41(15):1229–1245.
   PubMed Web of Science ®Google Scholar
• Huang X, Moreton FC, Kalladka D, et al. Coagulation and fibrinolytic activity of tenecteplase and alteplase in acute ischemic stroke. Stroke. 2015;46(12):3543–3546.
   PubMed Web of Science ®Google Scholar
• Haley EC Jr, Thompson JL, Grotta JC, et al. Phase IIB/III trial of tenecteplase in acute ischemic stroke: results of a prematurely terminated randomized clinical trial. Stroke. 2010;41(4):707–711.
   PubMed Web of Science ®Google Scholar
• Parsons M, Spratt N, Bivard A, et al. A randomized trial of tenecteplase versus alteplase for acute ischemic stroke. N Engl J Med. 2012;366(12):1099–1107.
   PubMed Web of Science ®Google Scholar
• Huang X, Cheripelli BK, Lloyd SM, et al. Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study. Lancet Neurol. 2015;14(4):368–376.
   PubMed Web of Science ®Google Scholar
• Huang X, MacIsaac R, Thompson JL, et al. Tenecteplase versus alteplase in stroke thrombolysis: an individual patient data meta-analysis of randomized controlled trials. Int J Stroke. 2016;11(5):534–543.
   PubMed Web of Science ®Google Scholar
• Chen X, Wang K. The fate of medications evaluated for ischemic stroke pharmacotherapy over the period 1995-2015. Acta Pharm Sin B. 2016;6(6):522–530.
   PubMed Web of Science ®Google Scholar